Literature DB >> 25806329

Targeting MET in NSCLC: looking for a needle in a haystack.

Lorenza Landi1, Federico Cappuzzo1.   

Abstract

Entities:  

Year:  2014        PMID： 25806329      PMCID： PMC4367673          DOI： 10.3978/j.issn.2218-6751.2014.11.05

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  6 in total

1.  MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.

Authors:  Junko Tanizaki; Isamu Okamoto; Kunio Okamoto; Ken Takezawa; Kiyoko Kuwata; Haruka Yamaguchi; Kazuhiko Nakagawa
Journal:  J Thorac Oncol       Date:  2011-10       Impact factor: 15.609

Review 2.  Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Authors:  Jeffrey A Engelman; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

3.  Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

Authors:  David R Spigel; Thomas J Ervin; Rodryg A Ramlau; Davey B Daniel; Jerome H Goldschmidt; George R Blumenschein; Maciej J Krzakowski; Gilles Robinet; Benoit Godbert; Fabrice Barlesi; Ramaswamy Govindan; Taral Patel; Sergey V Orlov; Michael S Wertheim; Wei Yu; Jiping Zha; Robert L Yauch; Premal H Patel; See-Chun Phan; Amy C Peterson
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

4.  MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

Authors:  F Cappuzzo; P A Jänne; M Skokan; G Finocchiaro; E Rossi; C Ligorio; P A Zucali; L Terracciano; L Toschi; M Roncalli; A Destro; M Incarbone; M Alloisio; A Santoro; M Varella-Garcia
Journal:  Ann Oncol       Date:  2008-10-03       Impact factor: 32.976

5.  Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752.

Authors:  Gromoslaw A Smolen; Raffaella Sordella; Beth Muir; Gayatry Mohapatra; Anne Barmettler; Heidi Archibald; Woo J Kim; Ross A Okimoto; Daphne W Bell; Dennis C Sgroi; James G Christensen; Jeffrey Settleman; Daniel A Haber
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-06       Impact factor: 11.205

6.  Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.

Authors:  Federico Cappuzzo; Antonio Marchetti; Margaret Skokan; Elisa Rossi; Sujatha Gajapathy; Lara Felicioni; Maela Del Grammastro; Maria Grazia Sciarrotta; Fiamma Buttitta; Matteo Incarbone; Luca Toschi; Giovanna Finocchiaro; Annarita Destro; Luigi Terracciano; Massimo Roncalli; Marco Alloisio; Armando Santoro; Marileila Varella-Garcia
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544
  6 in total
  5 in total

1.  Impact of a five-dimensional framework on R&D productivity at AstraZeneca.

Authors:  Paul Morgan; Dean G Brown; Simon Lennard; Mark J Anderton; J Carl Barrett; Ulf Eriksson; Mark Fidock; Bengt Hamrén; Anthony Johnson; Ruth E March; James Matcham; Jerome Mettetal; David J Nicholls; Stefan Platz; Steve Rees; Michael A Snowden; Menelas N Pangalos
Journal:  Nat Rev Drug Discov       Date:  2018-01-19       Impact factor: 84.694

2.  89Zr-Onartuzumab PET imaging of c-MET receptor dynamics.

Authors:  Martin Pool; Anton G T Terwisscha van Scheltinga; Arjan Kol; Danique Giesen; Elisabeth G E de Vries; Marjolijn N Lub-de Hooge
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-19       Impact factor: 9.236

Review 3.  Role of cytokines in combinatorial immunotherapeutics of non-small cell lung cancer through systems perspective.

Authors:  Pragya Misra; Shailza Singh
Journal:  Cancer Med       Date:  2019-04-17       Impact factor: 4.452

4.  Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.

Authors:  Xuyuan Dong; Ester Fernandez-Salas; Enxiao Li; Shaomeng Wang
Journal:  Neoplasia       Date:  2016-03       Impact factor: 5.715

Review 5.  Na/K Pump and Beyond: Na/K-ATPase as a Modulator of Apoptosis and Autophagy.

Authors:  Cassiano Felippe Gonçalves-de-Albuquerque; Adriana Ribeiro Silva; Camila Ignácio da Silva; Hugo Caire Castro-Faria-Neto; Patrícia Burth
Journal:  Molecules       Date:  2017-04-21       Impact factor: 4.411
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.